Amneal receives u.s. fda approval for prednisolone acetate ophthalmic suspension

Bridgewater, n.j., june 12, 2025 (globe newswire) -- amneal pharmaceuticals, inc. (“amneal” or the “company”) today announced the u.s. food and drug administration (fda) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references pred forte®. pred forte and its design are trademarks of allergan, inc., an abbvie company. launch of this product is planned for the third quarter of 2025.
AMRX Ratings Summary
AMRX Quant Ranking